Shionogi's first-half profit rises as revenue climbs 64.5%
Japan's Shionogi reported higher first-half profit and revenue, with sales up 64.5%, and gave full-year EPS and revenue guidance for the year ahead.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Japanese drugmaker Shionogi & Co., Ltd. (SGIOF) reported a higher profit for the first half compared with the same period last year, according to TradingView, which cited RTTNews and dpa-AFX. Net profit came in at JPY119.546 billion, or JPY140.43 per share, versus JPY82.999 billion, or JPY97.52 per share, a year earlier.
Revenue for the period rose 64.5% to JPY350.377 billion from JPY212.965 billion a year earlier. The company also issued full-year guidance of JPY249.67 in EPS and JPY720 billion in revenue, with the EPS figure based on basic earnings.
why it matters
For investors, the pace of growth matters: both revenue and profit increased much faster than last year, which typically supports interest in a large Japanese pharma stock. A single company's results rarely move the index, but Shionogi's figures help gauge the health of Japan's pharmaceutical sector and expectations for its earnings.
market impact
Shionogi shares: strong profit and revenue growth supports investor interest
- Shionogi shares pressure up — strong profit and revenue growth supports investor interest
tags
instruments
sources
- Shionogi & Co., Ltd. Bottom Line Advances In H1 — TradingView, 29 October 2026 at 04:54 UTC
- Tokyo Gas Co.,Ltd. Reveals Fall In H1 Bottom Line — TradingView, 29 October 2026 at 05:46 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗